Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neurofibromatosis 2 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 2a 1Medulloblastoma 1Lethal Congenital Contracture Syndrome 2 1Hemangiosarcoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 18Ifosfamide 13Radiotherapy 8Paclitaxel 7pazopanib 6pembrolizumab 4Gemcitabine 4Filgrastim 4Chemotherapy, Adjuvant 4Bevacizumab 4spartalizumab 3durvalumab 3Sorafenib 3Propranolol 3Nivolumab 3Ipilimumab 3Imatinib Mesylate 3Etoposide 3Epirubicin 3Docetaxel 3Carboplatin 3trebananib 2regorafenib 2cixutumumab 2cemiplimab 2carotuximab 2brostallicin 2belinostat 2balstilimab 2Vincristine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hemangiosarcoma × Vascular Endothelial Growth Factor A × Clear all
NCT00288015 2018-06-25

Bevacizumab in Treating Patients With Angiosarcoma

Northwestern University

Phase 2 Completed
32 enrolled 12 charts
Sarcoma

Hemangiosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡